Darapladib effect on circulating high sensitive troponin in patients with acute coronary syndromes

► Diabetes was associated with a higher incidence of 2-fold increases in hs-cTnI levels. ► There was a marked suppression of the late elevation (>13 weeks) of high sensitivity Troponin I in patients treated with darapladib. ► This marked suppression was more apparent in patients that had Acute Coronary Syndromes (ACS) at the time of randomization to darapladib.